News | August 09, 2010

Invatec's Purchase May Bolster U.S. Balloon Market Share

August 9, 2010 – According to Millennium Research Group (MRG), a medical technology market research company, Invatec has traditionally held a much stronger position in the European percutaneous transluminal angioplasty (PTA) balloon catheter market compared to the United States. Nonetheless, sales of Invatec's PTA balloon catheters picked up in the United States in the first quarter of 2010, according to MRG's Peripheral Vascular Marketrack study, coinciding with Medtronic's announcement it would purchase the company. Further success of the Invatec product lines in the United States will be bolstered by Medtronic's established sales and marketing efforts.

Invatec, whose purchase by Medtronic was finalized in April, is known for its high-quality PTA product line for the treatment of peripheral artery disease, especially in Europe, where the company was the fourth-leading competitor in the PTA balloon catheter market in 2009.

Conversely, Invatec products captured approximately 5 percent of the U.S. PTA balloon catheter market in 2009, where it offered only a selection of its products. Medtronic's acquisition of Invatec is expected to benefit both companies and has the potential for a synergistic relationship -- with Medtronic broadening its peripheral vascular product line and Invatec expanding its presence in the US market.

"Invatec has traditionally maintained only a small presence in the U.S. PTA balloon catheter market, meaning significant opportunity exists for Medtronic to expand the presence of these product lines in the U.S.," said Stephanie Labelle, manager of the cardiovascular division at MRG.
"The Invatec product line will benefit from Medtronic's existing relationships with physicians using its drug-eluting coronary stents and aortic stent grafts, therefore expanding Invatec's penetration into U.S. facilities. In addition, Medtronic may consider bringing additional Invatec products to the U.S. marketplace that would further increase the company's share of the peripheral vascular device market, including the In.Pact Admiral drug-eluting balloon, the Cristallo Ideale carotid stent, and the innovative Mo.Ma Ultra embolic protection device, which are currently available in Europe, and would further increase the company's competitiveness in the U.S. peripheral vascular device market."

MRG's Peripheral Vascular Marketrack project gathers facility level procedure and product usage data on treatments for peripheral artery disease. Data is collected on a monthly basis in the United States and a quarterly basis in Europe from interventional radiology labs, interventional cardiology labs, and operating rooms throughout the United States and Europe. Marketrack subscribers receive thousands of data points, including usage (units, average selling price, and revenue), procedure, competitor, and brand information.

For more information:

Related Content

Medtronic Launches Concerto 3-D Detachable Coil System
News | Embolization devices| October 16, 2017
October 16, 2017 — Medtronic announced the launch of the Concerto 3-D Detachable Coil System at the Cardiovascular an
Avinger Receives CE Mark for In-Stent Restenosis Indication With Pantheris Image-Guided Atherectomy
Technology | Atherectomy Devices| September 29, 2017
Avinger Inc. recently announced Conformité Européenne (CE) Marking approval for treating in-stent restenosis with the...
Spectranetics Initiates Class I Recall for Bridge Occlusion Balloon Catheter
News | EP Lab| September 27, 2017
Spectranetics is recalling its Bridge Occlusion Balloon Catheter due to the possibility of a blocked guidewire lumen in...
Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Lesion Preparation Via Atherectomy Enhances Paclitaxel Distribution in Calcified Peripheral Arteries
News | Peripheral Artery Disease (PAD)| September 20, 2017
September 20, 2017 — Not-for-profit preclinical research institute CBSET announced that its scientists have published
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Philips Showcases Integrated Vascular Solutions at VIVA 2017
News | Peripheral Artery Disease (PAD)| September 13, 2017
Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from...
Overlay Init